British Journal of Cancer

Table 5 Nonhaematologic toxicities

From: A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer

	Phase I
Dose level	60N	60P	65P	70P	75P	80P	Phase II
Number of patients (cycles)	7 (13)	5 (8)	5 (14)	4 (9)	6 (15)	2 (2)	48 (140)
Fatigue
Grade 2	0	1 (1)	1 (1)	0	0	0	12 (16)
Grade 3	0	0	0	0	0	2 (2)	2 (2)
Grade 4	0	0	0	0	0	0	0
Nausea
Grade 2	5 (8)	3 (3)	3 (6)	3 (5)	5 (10)	0	24 (40)
Grade 3	0	1 (1)	0	1 (1)	0	2 (2)	7 (10)
Grade 4	0	0	0	0	0	0	0
Infection
Grade 2	1 (1)	0	1 (2)	2 (2)	1 (1)	0	9 (14)
Grade 3	1 (1)	0	0	0	0	0	1 (1)
Grade 4	0	0	0	0	0	0	0
+NPG^a ⩾3	1 (1)	0	0	0	1 (1)	2 (2)	11 (13)
Early diarrhoea
Grade 2	1 (1)	1 (2)	1 (1)	1 (1)	3 (4)	0	17 (23)
Grade 3	0	0	0	0	0	1 (1)	1 (1)
Grade 4	0	0	0	0	0	0	0
Late diarrhoea
Grade 2	2 (2)	2 (2)	2 (3)	1 (1)	2 (3)	0	7 (9)
Grade 3	0	0	0	0	0	0	3 (3)
Grade 4	0	0	0	0	0	2 (2)	0
Total bilirubin
Grade 2	1 (1)	0	1 (2)	1 (3)	1 (1)	2 (2)	7 (13)
Grade 3	0	0	0	1 (1)	0	0	4 (4)
Grade 4	0	0	0	0	0	0	0
Transaminases
Grade 2	0	0	0	0	0	0	3 (5)
Grade 3	0	0	0	0	1 (2)	0	3 (6)
Grade 4	0	0	0	0	0	0	0
Hyponatremia
Grade 2	2 (3)	0	0	0	2 (2)	0	11 (17)
Grade 3	1 (1)	0	0	1 (1)	0	1 (1)	1 (1)
Grade 4	0	0	0	0	0	0	0

^aNeutropenia grade.

Back to article page

Search

Advanced search

Quick links